Results showed 46.45 and 72.74% increases in the global incidences of acute infection and HCV-related cirrhosis, respectively, in reproductive-age women.
The April 2024 month in review features HCPLive’s top coverage of resmetirom, other key hepatic pipeline updates, and recent research about hepatitis C virus.
Findings highlight an increase in hospitalization among pregnant patients with HCV, further describing age’s impact on mortality, cirrhosis, preterm births, and stillbirths.
Tenofovir disoproxil fumarate was safe and effective for preventing mother-to-child transmission of HBV, but discontinuation was linked to postpartum hepatitis flares.